Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas
Journal of Korean Medical Science
; : 565-570, 1999.
Article
in En
| WPRIM
| ID: wpr-187360
Responsible library:
WPRO
ABSTRACT
The benefits of radio-chemotherapy in HIV-negative primary central nervous system (CNS) lymphomas were analyzed in 40 patients, who received radiotherapy to the brain or craniospinal axis with the total dose of 4460-5940 cGy to the primary tumor. Radiotherapy was followed by systemic chemotherapy, mainly with the cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen, in 16 of the patients. Follow-up ranged from four to 95 months with a median of 15 months. The relapse rate was 72.5%, and 83% of the relapses occurred within the radiation field. Median survival was 19 months and the two-year survival rate was 41%. Survival was significantly influenced by treatment method and radiation dose when measured by univariate analysis; median survival and the two-year survival rate was 29 months and 63% after radio-chemotherapy, while 13.5 month and 29% after radiotherapy alone (p= 0.027), and 22 months and 49% with doses of 50 Gy or more, but 12.5 months and 13% with doses less than 50 Gy (p=0.009). However, statistical significance was lost in multivariate analysis. These results might suggest the short-term efficacy of radio-chemotherapy, however, cautious observation is needed to confirm long-term effects.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Procarbazine
/
Radiotherapy Dosage
/
Vincristine
/
Bleomycin
/
Prednisolone
/
Epirubicin
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Methotrexate
/
Survival Rate
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Journal of Korean Medical Science
Year:
1999
Type:
Article